J. Goldman & CO LP Avadel Pharmaceuticals PLC Transaction History

J. Goldman & CO LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $1.39 Million - $2.15 Million	134,609 Added 467.83%	163,382 $1.68 Million
Q2 2023 Aug 14, 2023	SELL	$8.48 - $16.48 $1.29 Million - $2.51 Million	-152,227 Reduced 84.1%	28,773 $474,000
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $684,267 - $1.06 Million	106,750 Added 143.77%	181,000 $1.66 Million
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $372,734 - $742,500	74,250 New	74,250 $531,000
Q1 2021 May 17, 2021	SELL	$6.61 - $10.07 $1.55 Million - $2.35 Million	-233,747 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $879,636 - $1.39 Million	-174,878 Reduced 42.8%	233,747 $1.56 Million
Q3 2020 Nov 16, 2020	SELL	$5.02 - $8.98 $1.2 Million - $2.15 Million	-239,083 Reduced 36.91%	408,625 $2.06 Million
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $4.7 Million - $7.61 Million	647,708 New	647,708 $5.23 Million
Q1 2018 May 15, 2018	SELL	$6.76 - $11.7 $520,520 - $900,900	-77,000 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$8.03 - $11.25 $2.53 Million - $3.54 Million	-314,839 Reduced 80.35%	77,000 $631,000
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $3.27 Million - $4.11 Million	391,839	391,839 $4.11 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $478M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.